Activation of platelet-activating factor receptor exacerbates renal inflammation and promotes fibrosis

Laboratory Investigation

Volumn 94, Issue 4, 2014, Pages 455-466

  Correa Costa, Matheus ^a   Andrade Oliveira, Vinicius ^a   Braga, Tarcio T ^a   Castoldi, Angela ^a   Aguiar, Cristhiane F ^a   Origassa, Clarice S T ^b   Rodas, Andrea C D ^a   Hiyane, Meire I ^a   Malheiros, Denise M A C ^a   Rios, Francisco J O ^a,c   Jancar, Sonia ^a   Câmara, Niels O S ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

chronic kidney disease; platelet activating factor receptor; renal fibrosis; renal inflammation

Indexed keywords

ALPHA INTERFERON; BEPAFANT; CELL ADHESION MOLECULE; COLLAGEN TYPE 1; CREATININE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOGENIC PROTEIN 1; PROTEIN; PROTEIN LYSINE 6 OXIDASE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE URINE LEVEL; CYTOKINE PRODUCTION; DIABETIC NEPHROPATHY; DISEASE EXACERBATION; DOWN REGULATION; DRUG EFFECT; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY PARENCHYMA; KNOCKOUT MOUSE; MOUSE; NEPHRITIS; NONHUMAN; OBSTRUCTIVE UROPATHY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; URETER OBSTRUCTION; URINALYSIS; WILD TYPE;

ANIMALS; AZEPINES; COLLAGEN; DISEASE MODELS, ANIMAL; FIBROSIS; KIDNEY; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEPHRITIS; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, G-PROTEIN-COUPLED; RENAL INSUFFICIENCY, CHRONIC; TRIAZOLES; URETERAL OBSTRUCTION;

EID: 84897374606     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2013.155     Document Type: Article

References (64)

1. Prunotto M, Budd DC, Gabbiani G, et al. Epithelial-mesenchymal crosstalk alteration in kidney fibrosis. J Pathol 2012
2. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-2047
3. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 2011;7:684-696
4. Oliveira de Lima A, Kesrouani S, Gomes RA, et al. Population screening for chronic kidney disease: A survey involving 38 721 Brazilians. Nephrol Dial Transplant 2012;(Suppl 3):iii 135-138
5. Sharma SK, Zou H, Togtokh A, et al. Burden of CKD, proteinuria, and cardiovascular risk among Chinese, Mongolian, and Nepalese participants in the International Society of Nephrology screening programs. Am J Kidney Dis 2010;56:915-927
6. Prunotto M, Budd DC, Meier M, et al. From acute injury to chronic disease: Pathophysiological hypothesis of an epithelial/mesenchymal crosstalk alteration in CKD. Nephrol Dial Transplant 2012;(Suppl 3):iii 43-50
7. Lopez-Novoa JM, Nieto MA. Inflammation and EMT: An alliance towards organ fibrosis and cancer progression. EMBO Mol Med 2009;1:303-314
8. Strutz F, Okada H, Lo CW, et al. Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 1995;130:393-405
9. Chandrasekaran K, Karolina DS, Sepramaniam S, et al. Role of microRNAs in kidney homeostasis and disease. Kidney Int 2012;81: 617-627
10. Dooley S, ten Dijke P. TGF-beta in progression of liver disease. Cell Tissue Res 2012;347:245-256
11. Hackett TL. Epithelial-mesenchymal transition in the pathophysiology of airway remodelling in asthma. Curr Opin Allergy Clin Immunol 2012;12:53-59
12. Kovacic JC, Mercader N, Torres M, et al. Epithelial-To-mesenchymal and endothelial-To-mesenchymal transition: From cardiovascular development to disease. Circulation 2012;125:1795-1808
13. Sipos F, Galamb O. Epithelial-To-mesenchymal and mesenchymalto- epithelial transitions in the colon. World J Gastroenterol 2012;18: 601-608
14. Schlondorff D, Neuwirth R. Platelet-Activating factor and the kidney. Am J Physiol 1986;251(1 Pt 2):F1-11
15. Ishii S, Nagase T, Shimizu T. Platelet-Activating factor receptor. Prostaglandins Other Lipid Mediat 2002;68-69:599-609
16. Rios FJ, Koga MM, Ferracini M, et al. Co-stimulation of PAFR and CD36 is required for oxLDL-induced human macrophages activation. PLoS ONE 2012;7:e36632
17. Lopez-Novoa JM. Potential role of platelet activating factor in acute renal failure. Kidney Int 1999;55:1672-1682
18. Ishii S, Kuwaki T, Nagase T, et al. Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-Activating factor receptor. J Exp Med 1998;187:1779-1788
19. Correa-Costa M, Semedo P, Monteiro AP, et al. Induction of heme oxygenase-1 can halt and even reverse renal tubule-interstitial fibrosis. PLoS ONE 2010;5:e14298
20. Rodriguez C, Rodriguez-Sinovas A, Martinez-Gonzalez J. Lysyl oxidase as a potential therapeutic target. Drug News Perspect 2008;21:218-224
21. Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-beta1- induced epithelial-To-mesenchymal transition and reverses chronic renal injury. Nat Med 2003;9:964-968
22. Lee SB, Kalluri R. Mechanistic connection between inflammation and fibrosis. Kidney Int Suppl 2010;119:S22-S26
23. Duitman J, Schouten M, Groot AP, et al. CCAAT/enhancer-binding protein delta facilitates bacterial dissemination during pneumococcal pneumonia in a platelet-Activating factor receptor-dependent manner. Proc Natl Acad Sci US A 2012;109:9113-9118
24. Hasegawa S, Kohro Y, Shiratori M, et al. Role of PAF receptor in proinflammatory cytokine expression in the dorsal root ganglion and tactile allodynia in a rodent model of neuropathic pain. PLoS ONE 2010;5:e10467
25. Lu J, Jilling T, Li D, et al. Polyunsaturated fatty acid supplementation alters proinflammatory gene expression and reduces the incidence of necrotizing enterocolitis in a neonatal rat model. Pediatr Res 2007;61:427-432
26. Castor MG, Rezende BM, Resende CB, et al. Platelet-Activating factor receptor plays a role in the pathogenesis of graft-versus-host disease by regulating leukocyte recruitment, tissue injury, and lethality. J Leukoc Biol 2012;91:629-639
27. Zimmerman GA, McIntyre TM, Prescott SM, et al. The plateletactivating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 2002;30(5 Suppl): S294-S301
28. Rios FJ, Ferracini M, Pecenin M, et al. Uptake of oxLDL and IL-10 production by macrophages requires PAFR and CD36 recruitment into the same lipid rafts. PLoS ONE 2013;8:e76893
29. Rios FJ, Koga MM, Pecenin M, et al. Oxidized LDL induces alternative macrophage phenotype through activation of CD36 and PAFR. Mediators Inflamm 2013;2013:198193
30. Ribeiro S, Faria Mdo S, Silva G, et al. Oxidized low-density lipoprotein and lipoprotein(a) levels in chronic kidney disease patients under hemodialysis: Influence of adiponectin and of a polymorphism in the apolipoprotein(a) gene. Hemodial Int Int Symp Home Hemodial 2012;16:481-490
31. Chen Z, Rola-Pleszczynski M, Stankova J. Activation of ERK1/2 by platelet-Activating factor receptor is independent of receptor internalisation and G-protein activation. Cell Signal 2003;15:843-850
32. Gonzalez-Ramos M, Calleros L, Lopez-Ongil S, et al. HSP70 increases extracellular matrix production by human vascular smooth muscle through TGF-beta1 up-regulation. Int J Biochem Cell Biol 2013;45:232-242
33. Mariano F, Guida G, Donati D, et al. Production of platelet-Activating factor in patients with sepsis-Associated acute renal failure. Nephrol Dial Transplant 1999;14:1150-1157
34. Cravedi P, Ruggenenti P, Remuzzi G. Proteinuria should be used as a surrogate in CKD. Nat Rev Nephrol 2012;8:301-306
35. Perico N, Lapinski R, Konopka K, et al. Platelet-Activating factor mediates angiotensin II-induced proteinuria in isolated perfused rat kidney. J Am Soc Nephrol 1997;8:1391-1398
36. Torras J, Cruzado JM, Riera M, et al. Long-Term protective effect of UR-12670 after warm renal ischemia in uninephrectomized rats. Kidney Int 1999;56:1798-1808
37. Thaiss F, Mihatsch MJ, Oberle G, et al. Platelet-Activating factor receptor antagonist improves renal function and glomerular lesions in renal ablation. J Lab Clin Med 1994;124:775-781
38. Camussi G, Tetta C, Coda R, et al. Platelet-Activating factor-induced loss of glomerular anionic charges. Kidney Int 1984;25:73-81
39. Chen J, Ziboh V, Giri SN. Up-regulation of platelet-Activating factor receptors in lung and alveolar macrophages in the bleomycin-hamster model of pulmonary fibrosis. J Pharmacol Exp Therap 1997;280: 1219-1227
40. Karantonis HC, Gribilas G, Stamoulis I, et al. Platelet-Activating factor involvement in thioacetamide-induced experimental liver fibrosis and cirrhosis. Dig Dis Sci 2010;55:276-284
41. Doi K, Okamoto K, Negishi K, et al. Attenuation of folic acid-induced renal inflammatory injury in platelet-Activating factor receptordeficient mice. Am J Pathol 2006;168:1413-1424
42. Ruiz-Ortega M, Bustos C, Plaza JJ, et al. Overexpression of extracellular matrix proteins in renal tubulointerstitial cells by platelet-Activatingfactor stimulation. Nephrol Dial Transplant 1998;13:886-892
43. Braga TT, Correa-Costa M, Guise YF, et al. MyD88 signaling pathway is involved in renal fibrosis by favoring a TH2 immune response and activating alternative M2 macrophages. Mol Med (Cambridge, MA) ;18:1231-1239
44. Correa-Costa M, Braga TT, Semedo P, et al. Pivotal role of Toll-like receptors 2 and 4, its adaptor molecule MyD88, and inflammasome complex in experimental tubule-interstitial nephritis. PLoS ONE 2011;6:e29004
45. Lacerda-Queiroz N, Rodrigues DH, Vilela MC, et al. Platelet-Activating factor receptor is essential for the development of experimental cerebral malaria. Am J Pathol 2012;180:246-255
46. Rodrigues DH, Lacerda-Queiroz N, de Miranda AS, et al. Absence of PAF receptor alters cellular infiltrate but not rolling and adhesion of leukocytes in experimental autoimmune encephalomyelitis. Brain Res 2012;1385:298-306
47. Sharif NA, Wiernas TK. Platelet-Activating factor-induced intracellular signaling and release of cytokines and prostaglandin E2 in immortalized human corneal epithelial cells. J Ocul Pharmacol Ther 2010;26:21-29
48. Sharma J, Young DM, Marentette JO, Rastogi P, Turk J, McHowat J. Lung endothelial cell platelet-Activating factor production and inflammatory cell adherence are increased in response to cigarette smoke component exposure. Am J Physiol Lung Cell Mol Physiol 2012;302:L47-L55
49. Ishii S, Shimizu T. Platelet-Activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Prog Lipid Res 2000;39:41-82
50. Venkatesha RT, Ahamed J, Nuesch C, Zaidi AK, Ali H. Platelet-Activating factor-induced chemokine gene expression requires NF-kappaB activation and Ca2+/calcineurin signaling pathways. Inhibition by receptor phosphorylation and beta-Arrestin recruitment. J Biol Chem 2004;279:44606-44612
51. Fadok VA, Bratton DL, Henson PM. Phagocyte receptors for apoptotic cells: Recognition, uptake, and consequences. J Clin Invest 2001;108: 957-962
52. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5:953-964
53. Bascands JL, Schanstra JP. Obstructive nephropathy: Insights from genetically engineered animals. Kidney Int 2005;68:925-937
54. Bennett SA, Chen J, Pappas BA, Roberts DC, Tenniswood M. Platelet activating factor receptor expression is associated with neuronal apoptosis in an in vivo model of excitotoxicity. Cell Death Differ 1998;5:867-875
55. Chen CH, Jiang T, Yang JH, Jiang W, Lu J, Marathe GK, et al. Lowdensity lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation 2003;107:2102-2108
56. Ryan SD, Harris CS, Mo F, Lee H, Hou ST, Bazan NG, et al. Platelet activating factor-induced neuronal apoptosis is initiated independently of its G-protein coupled PAF receptor and is inhibited by the benzoate orsellinic acid. J Neurochem 2007;103:88-97
57. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-218
58. Bedi S, Vidyasagar A, Djamali A. Epithelial-To-mesenchymal transition and chronic allograft tubulointerstitial fibrosis. Transplant Rev (Orlando) 2008;22:1-5
59. Chung AC, Huang XR, Zhou L, Heuchel R, Lai KN, Lan HY. Disruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (UUO) in mice. Nephrol Dial Transplant 2009;24:1443-1454
60. Hwang M, Kim HJ, Noh HJ, Chang YC, Chae YM, Kim KH, et al. TGFbeta1 siRNA suppresses the tubulointerstitial fibrosis in the kidney of ureteral obstruction. Exp Mol Pathol 2006;81:48-54
61. Wang S, Chen Q, Simon TC, Strebeck F, Chaudhary L, Morrissey J, et al. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 2003;63:2037-2049
62. Zeisberg M, Bottiglio C, Kumar N, Maeshima Y, Strutz F, Muller GA, et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol 2003;285:F1060-F1067
63. Zeisberg M, Kalluri R. The role of epithelial-To-mesenchymal transition in renal fibrosis. J Mol Med (Berlin, Germany) 2004;82:175-181
64. Zeisberg M, Shah AA, Kalluri R. Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J Biol Chem 2005;280: 8094-8100